FDA Approves Merck's Pneumococcal Vaccine for Adults
👉 Key Highlights:
📍 FDA approves Merck’s Capvaxive vaccine for pneumococcal disease.
📍 Capvaxive protects against 21 strains of pneumococcus bacteria.
📍 First pneumococcal conjugate vaccine designed specifically for adults.
📍 Targets severe pneumococcal disease, including pneumonia and meningitis.
📍 150,000 U.S. adults hospitalized annually with invasive pneumococcal disease.
📍 Merck expects rapid uptake and significant market share capture.
📍 CDC advisory panel to discuss vaccine eligibility on June 27.
📍 Merck aims to supply the vaccine by late summer.
👉 Market Insights:
📍 The pneumococcal vaccine market could grow to over $10 billion in the next few years.
📍 Merck's new vaccine is expected to compete strongly against Pfizer’s Prevnar 20.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
AI-Powered Insights at a Glance: Crystal-clear earnings reports & vital stock news.
699Followers
13Following
1531Visitors
Follow